Amit G Singal1, Saurabh P Nagar2, Abby Hitchens2, Keith L Davis2, Shrividya Iyer3. 1. Division of Digestive & Liver Disease, UT Southwestern Medical Center, Dallas, TX 75390, USA. 2. Department of Health Economics, RTI Health Solutions, Research Triangle Park, NC 27709, USA. 3. Global Real World Evidence & US HEOR, Eisai, Inc., Woodcliff Lake, NJ 07677, USA.
Abstract
Aim: This study evaluated the effectiveness of lenvatinib monotherapy for first-line treatment of unresectable hepatocellular carcinoma (uHCC) in a real-world setting. Materials & methods: This retrospective cohort study included patients who initiated lenvatinib monotherapy as first-line treatment for uHCC (n = 233). Clinical outcomes included provider-reported best response, progression-free survival (PFS) and overall survival (OS). PFS and OS were estimated using Kaplan-Meier methods. Results: Most patients (67.8%) were male. A total of 44.6% had Child-Pugh A and 39.1% had Child-Pugh B. Dose reductions were reported in 9%. Median PFS and OS were not reached. At 6 and 12 months, landmark PFS were 85.1 and 64.9%, respectively; landmark OS were 91.8 and 72.6%, respectively. Conclusion: These results affirm the clinical effectiveness of first-line lenvatinib monotherapy in uHCC.
Aim: This study evaluated the effectiveness of lenvatinib monotherapy for first-line treatment of unresectable hepatocellular carcinoma (uHCC) in a real-world setting. Materials & methods: This retrospective cohort study included patients who initiated lenvatinib monotherapy as first-line treatment for uHCC (n = 233). Clinical outcomes included provider-reported best response, progression-free survival (PFS) and overall survival (OS). PFS and OS were estimated using Kaplan-Meier methods. Results: Most patients (67.8%) were male. A total of 44.6% had Child-Pugh A and 39.1% had Child-Pugh B. Dose reductions were reported in 9%. Median PFS and OS were not reached. At 6 and 12 months, landmark PFS were 85.1 and 64.9%, respectively; landmark OS were 91.8 and 72.6%, respectively. Conclusion: These results affirm the clinical effectiveness of first-line lenvatinib monotherapy in uHCC.
Authors: Kurvi Patwala; David Stephen Prince; Yael Celermajer; Waafiqa Alam; Eldho Paul; Simone Irene Strasser; Geoffrey William McCaughan; Paul Gow; Siddharth Sood; Elise Murphy; Stuart Roberts; Elliot Freeman; Elizabeth Stratton; Scott Anthony Davison; Miriam Tania Levy; McCawley Clark-Dickson; Vi Nguyen; Sally Bell; Amanda Nicoll; Ashley Bloom; Alice Unah Lee; Marno Ryan; Jessica Howell; Zina Valaydon; Alexandra Mack; Ken Liu; Anouk Dev Journal: Hepatol Int Date: 2022-08-25 Impact factor: 9.029